Abstract

Background: It has previously been demonstrated that erythropoietin (Epo) protects against focal brain ischemia. Thus, clinical trials in human stroke patients have recently been initiated, which are currently performed. Unfortunately, the underlying mechanisms of action of Epo in vivo are still poorly understood. In order to elucidate this issue, transgenic mice overexpressing Epo in the central nervous system but not the rest of the body have recently been produced (so-called tg21 mice). We here examined the effects of Epo overexpression on neuronal injury after transient focal ischemia and retinal ganglion cell (RGC) axotomy.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.